Leading health imaging company, Pro Medicus Limited (ASX: PME) announced its wholly owned U.S. subsidiary, Visage Imaging, Inc. has signed an AUD $15 million, 7 year contract with the U.S. based Mercy health system for Visage 7 Open Archive.
The contract, based on a transaction licensing model, will see Pro Medicus’ Visage 7 Open Archive implemented across the Mercy healthcare enterprise, which is the fifth largest Catholic health system in the U.S., spanning 4 states.
“This is an industry defining deal for us,” said Dr Sam Hupert, Pro Medicus CEO. “We introduced our archive to the North American market because we saw the need for a scalable, interoperable, high performance archive which we felt was not being adequately addressed by others. This deal validates our strategy. Our customers now have the flexibility to extend the use of Visage 7 in a totally modular fashion across their enterprise.”
The project will involve the migration of more than 25 million diagnostic imaging exams from the current Mercy archive to Visage 7 Open Archive making it one of the largest medical imaging archives in North America. The project is scheduled to commence in late June 2018 and is to be completed in the third quarter of FY2019. The stock is currently trading at a market price of $7.79 (up 10.03% on June 28, 2018).
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.